DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH))

Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344) (2020) Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Influence of Sonographic Fetal Weight Estimation Inaccuracies in Macrosomia on Perinatal Outcome (2020) Pretscher J, Kehl S, Stelzl P, Stumpfe F, Mayr A, Schmid M, Staerk C, et al. Journal article Ultrasound Fetal Weight Estimation in Diabetic Pregnancies (2020) Pretscher J, Kehl S, Stumpfe FM, Mayr A, Schmid M, Schild RL, Beckmann M, Faschingbauer F Journal article Ultrasound Fetal Weight Estimation in Diabetic Pregnancies (2019) Pretscher J, Kehl S, Stumpfe FM, Mayr A, Schmid M, Schild RL, Beckmann M, Faschingbauer F Journal article Correlation of short-term variation and Doppler parameters with adverse perinatal outcome in low-risk fetuses at term (2019) Stumpfe FM, Kehl S, Pretscher J, Baier F, Bayer CM, Schwenke E, Schneider M, et al. Journal article Correlation of short-term variation and Doppler parameters with adverse perinatal outcome in small-for-gestational age fetuses at term (2019) Stumpfe FM, Faschingbauer F, Kehl S, Pretscher J, Stelzl P, Mayr A, Schild RL, et al. Journal article Can Sonographic Fetal Biometry Predict Adverse Perinatal Outcome? (2019) Pretscher J, Schwenke E, Baier F, Kehl S, Schneider M, Stumpfe FM, Schmid M, et al. Journal article Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study (2018) Schochter F, Rack B, Tzschaschel M, Polasik A, Andergassen U, Trapp E, Alunni-Fabbroni M, et al. Journal article